These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 29982712

  • 1. Serum immunoglobulin free light chains are sensitive biomarkers for monitoring disease activity and treatment response in primary Sjögren's syndrome.
    Verstappen GM, Moerman RV, van Nimwegen JF, van Ginkel MS, Bijzet J, Mossel E, Vissink A, Hazenberg BPC, Arends S, Kroese FGM, Bootsma H.
    Rheumatology (Oxford); 2018 Oct 01; 57(10):1812-1821. PubMed ID: 29982712
    [Abstract] [Full Text] [Related]

  • 2. Salivary free light chains and salivary immunoglobulins as potential non-invasive biomarkers in primary Sjögren's syndrome.
    Sandhya P, Kabeerdoss J, Christudoss P, Arulraj R, Mandal SK, Janardana R, Chebbi PP, Ganesan MP, Mahasampath G, Danda D.
    Int J Rheum Dis; 2022 Jan 01; 25(1):61-69. PubMed ID: 34791797
    [Abstract] [Full Text] [Related]

  • 3. Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome.
    Gottenberg JE, Aucouturier F, Goetz J, Sordet C, Jahn I, Busson M, Cayuela JM, Sibilia J, Mariette X.
    Ann Rheum Dis; 2007 Jan 01; 66(1):23-7. PubMed ID: 16569685
    [Abstract] [Full Text] [Related]

  • 4. Diagnostic accuracy of salivary and serum-free light chain assays in primary Sjögren's syndrome: a pilot study.
    Sandhya P, Christudoss P, Kabeerdoss J, Mandal SK, Aithala R, Mahasampath G, Job V, Danda D.
    Int J Rheum Dis; 2017 Jun 01; 20(6):760-766. PubMed ID: 28036132
    [Abstract] [Full Text] [Related]

  • 5. Serum soluble interleukin-2 receptor is a useful biomarker for disease activity but not for differential diagnosis in IgG4-related disease and primary Sjögren's syndrome adults from a defined population.
    Akiyama M, Sasaki T, Kaneko Y, Yasuoka H, Suzuki K, Yamaoka K, Takeuchi T.
    Clin Exp Rheumatol; 2018 Jun 01; 36 Suppl 112(3):157-164. PubMed ID: 29465360
    [Abstract] [Full Text] [Related]

  • 6. FcRL4+ B-cells in salivary glands of primary Sjögren's syndrome patients.
    Haacke EA, Bootsma H, Spijkervet FKL, Visser A, Vissink A, Kluin PM, Kroese FGM.
    J Autoimmun; 2017 Jul 01; 81():90-98. PubMed ID: 28390747
    [Abstract] [Full Text] [Related]

  • 7. Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren's syndrome. Data at enrollment in the prospective ASSESS cohort.
    Gottenberg JE, Seror R, Miceli-Richard C, Benessiano J, Devauchelle-Pensec V, Dieude P, Dubost JJ, Fauchais AL, Goeb V, Hachulla E, Hatron PY, Larroche C, Le Guern V, Morel J, Perdriger A, Puéchal X, Rist S, Saraux A, Sene D, Sibilia J, Vittecoq O, Nocturne G, Ravaud P, Mariette X.
    PLoS One; 2013 Jul 01; 8(5):e59868. PubMed ID: 23717383
    [Abstract] [Full Text] [Related]

  • 8. Serological lymphocytic activity and patient-reported outcomes in Sjögren's syndrome.
    Jülich M, Kanne AM, Sehnert B, Budweiser S, Voll RE, Kollert F.
    Clin Rheumatol; 2018 Sep 01; 37(9):2361-2366. PubMed ID: 29858711
    [Abstract] [Full Text] [Related]

  • 9. The evaluation of disease activity in Sjögren's syndrome based on the degree of MALT involvement: glandular swelling and cryoglobulinaemia compared to ESSDAI in a cohort study.
    De Vita S, Gandolfo S, Zandonella Callegher S, Zabotti A, Quartuccio L.
    Clin Exp Rheumatol; 2018 Sep 01; 36 Suppl 112(3):150-156. PubMed ID: 30156548
    [Abstract] [Full Text] [Related]

  • 10. Investigation of three potential autoantibodies in Sjogren's syndrome and associated MALT lymphoma.
    Cui L, Elzakra N, Xu S, Xiao GG, Yang Y, Hu S.
    Oncotarget; 2017 May 02; 8(18):30039-30049. PubMed ID: 28404907
    [Abstract] [Full Text] [Related]

  • 11. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.
    Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, Vissink A, Kallenberg CG, Bootsma H.
    Arthritis Rheum; 2005 Sep 02; 52(9):2740-50. PubMed ID: 16142737
    [Abstract] [Full Text] [Related]

  • 12. Could the complement component C4 or its fragment C4d be a marker of the more severe conditions in patients with primary Sjögren's syndrome?
    Sudzius G, Mieliauskaite D, Siaurys A, Viliene R, Butrimiene I, Characiejus D, Dumalakiene I.
    Rheumatol Int; 2014 Feb 02; 34(2):235-41. PubMed ID: 24166212
    [Abstract] [Full Text] [Related]

  • 13. Relationships between increased circulating YKL-40, IL-6 and TNF-α levels and phenotypes and disease activity of primary Sjögren's syndrome.
    Chen C, Liang Y, Zhang Z, Zhang Z, Yang Z.
    Int Immunopharmacol; 2020 Nov 02; 88():106878. PubMed ID: 32791244
    [Abstract] [Full Text] [Related]

  • 14. Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment.
    Delli K, Haacke EA, Kroese FG, Pollard RP, Ihrler S, van der Vegt B, Vissink A, Bootsma H, Spijkervet FK.
    Ann Rheum Dis; 2016 Nov 02; 75(11):1933-1938. PubMed ID: 26757748
    [Abstract] [Full Text] [Related]

  • 15. Serum CXCL13 levels are associated with lymphoma risk and lymphoma occurrence in primary Sjögren's syndrome.
    Traianos EY, Locke J, Lendrem D, Bowman S, Hargreaves B, Macrae V, UK primary Sjögren’s syndrome registry, Tarn JR, Ng WF.
    Rheumatol Int; 2020 Apr 02; 40(4):541-548. PubMed ID: 32047959
    [Abstract] [Full Text] [Related]

  • 16. Abatacept treatment of patients with primary Sjögren's syndrome results in a decrease of germinal centres in salivary gland tissue.
    Haacke EA, van der Vegt B, Meiners PM, Vissink A, Spijkervet FK, Bootsma H, Kroese FG.
    Clin Exp Rheumatol; 2017 Apr 02; 35(2):317-320. PubMed ID: 27908305
    [Abstract] [Full Text] [Related]

  • 17. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.
    Meiners PM, Arends S, Brouwer E, Spijkervet FK, Vissink A, Bootsma H.
    Ann Rheum Dis; 2012 Aug 02; 71(8):1297-302. PubMed ID: 22258489
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial.
    Baer AN, Gottenberg JE, St Clair EW, Sumida T, Takeuchi T, Seror R, Foulks G, Nys M, Mukherjee S, Wong R, Ray N, Bootsma H.
    Ann Rheum Dis; 2021 Mar 02; 80(3):339-348. PubMed ID: 33168545
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study).
    Meiners PM, Vissink A, Kroese FG, Spijkervet FK, Smitt-Kamminga NS, Abdulahad WH, Bulthuis-Kuiper J, Brouwer E, Arends S, Bootsma H.
    Ann Rheum Dis; 2014 Jul 02; 73(7):1393-6. PubMed ID: 24473674
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.